- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03750006
Enhancing Functional Capacity in Older Adults With Short Session High Intensity Interval Training (HIIT-VA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Enhancing functional capacity in older adults with short session high intensity interval training
Frailty is a condition of poor physiological reserve that increases susceptibility to falls, hospitalization, disability and mortality. The incidence of frailty rapidly increases after the age 65, growing from 10% to as many as 50% of those 85 years or older; therefore over 9 million Veterans are either frail or at risk for frailty. Exercise has proven benefits for frailty, yet older adults rarely attain the recommended 150 minutes a week of moderate intensity exercise. High intensity interval training (HIIT) is emerging as an alternative as it delivers similar or better gains than moderate intensity exercise in less time. Recently, the investigators published that a 3-day-a-week, 10-minute HIIT regimen in aged mice not only reduces frailty, but leads to both strength and endurance benefits. In addition, the preliminary data demonstrate significant changes in microRNA (miRNA) profiles. Despite the potential of short session HIIT to improve functional capacity and lead to better adherence, the modality has not been tested in individuals 65-85 years of age, and in particular, frail individuals. The goals of this proposal are to: 1) investigate the feasibility of recruiting and administering short session HIIT to frail, pre-frail, and non-frail older Veterans and 2) to characterize the physical performance benefits and serum microRNA (miRNA) profiles in those participants.
To accomplish these goals the investigators will administer a short session HIIT regimen totaling only 10-minutes, 3-days-a-week for 3 months, using recumbent exercise cycles, to 65-85 year old participants. The investigators will also utilize next generation RNA sequence technology to assess HIIT impacts upon microRNA profiles in serum samples. The investigators anticipate this project will demonstrate the feasibility of administering short session HIIT to older individuals, including vulnerable frail and pre-frail populations as well as demonstrate the ability to collect and analyze serum miRNA profiles. The advantages to this program are the ability to maintain or build muscle mass and improve aerobic conditioning, especially in older patients where frailty and sarcopenia are so prevalent. This pilot project will therefore lay the foundation for future clinical trials that further explore the utility of HIIT to prevent or delay the onset of frailty in larger cohorts, and ultimately lead to the enhancement of functional capacity and quality of life in aging Veteran populations.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14215
- VA Western New York Healthcare System, Buffalo, NY
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female
- Any race
- Frail, pre-frail, and non-frail
- Medical clearance for exercise
Exclusion Criteria:
- Severe co-morbidity (e.g. - CHF (class III), COPD (GOLD stage IV), CKD (stage 3))
- VAMC SLUMS score 20
- Physical impairment that prevents use of a recumbent exercise bike
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HIIT intervention
Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
|
Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline VO2 Max at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
VO2 max, also known as maximal oxygen uptake, will be assessed.
|
baseline and at participant completion, an average of 3 months
|
Change from baseline in physical activity enjoyment at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
Physical Activity Enjoyment Scale (PACES) that provides a valid instrument for assessing enjoyment in physical activity.
There are 18 subscales, each of which can receive a score from 1 to 7. Therefore the total range of the test spans summed scores from 18 to 126.
|
baseline and at participant completion, an average of 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the SPPB at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
Short Physical Performance Battery (SPPB) is an objective assessment tool for evaluating lower extremity functioning in older persons, including balance, side-by-side/semi-tandem/tandem stands, and gait speed.
There are 3 subscales, each of which can receive up to 4 points.
Therefore the total range of the test spans summed scores from 1 to 12.
|
baseline and at participant completion, an average of 3 months
|
Change from baseline in frailty phenotype at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
Fried frailty phenotype assessment including: gait speed, grip strength, endurance, activity level, weight loss. These scales report summed scores of 0 to 5. If gait speed or grip strength (m/sec or kg) falls within the lowest quintile (20%) fof the age and gender adjusted range, then it is given a score of "1". If both questions on the endurance or activity measures are positive then then it is given a score of "1". If weight loss is greater than 5% over the past year, then it is given a score of "1". |
baseline and at participant completion, an average of 3 months
|
Change from baseline in Quality of Life at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF).
There are 14 subscales with scores of 1 to 5. Therefore the total range of the test spans scores from 14 to 70.
|
baseline and at participant completion, an average of 3 months
|
Change from baseline in cognition at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
VA-SLUMS: VA Saint Louis University Mental Status screen.
|
baseline and at participant completion, an average of 3 months
|
Change from baseline in Activities of Daily Living & Instrumental Activities of Daily Living at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
ADLs: dressing, eating, ambulation, toileting, and hygiene IADLs: shopping, housework, accounting, food preparation, transportation/telephone
|
baseline and at participant completion, an average of 3 months
|
Change from baseline in microRNA profiling at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
Next Generation Sequencing of microRNA species from serum.
|
baseline and at participant completion, an average of 3 months
|
serum 25-hydroxy-vitamin D
Time Frame: baseline
|
serum 25-hydroxy-vitamin D
|
baseline
|
Change from baseline in C-reactive protein level at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
C-reactive protein
|
baseline and at participant completion, an average of 3 months
|
Change from baseline in quadriceps strength at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
Maximal quadriceps strength.
This will be measured with the MicroFET2 dynamometer with a readout in newtons.
|
baseline and at participant completion, an average of 3 months
|
Change from baseline in 6 minute walk distance at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
6 minute walk distance
|
baseline and at participant completion, an average of 3 months
|
Change from baseline in FRAIL scale at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
FRAIL scale: fatiguability, resistance, ambulation, illnesses, loss of weight.
If the answers to any of the questions is yes, then given score is "1" with a total survey range of 0 to 5.
|
baseline and at participant completion, an average of 3 months
|
Change from baseline in interleukin-6 level at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
Interleukin-6
|
baseline and at participant completion, an average of 3 months
|
Change from baseline in interleukin-10 level at 3 months
Time Frame: baseline and at participant completion, an average of 3 months
|
Interleukin-10
|
baseline and at participant completion, an average of 3 months
|
fNIRS
Time Frame: baseline and at participant completion, an average of 3 months
|
functional near infra-red spectroscopy to analyze muscle blood flow in the quadriceps during VO2max test
|
baseline and at participant completion, an average of 3 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Bruce R. Troen, MD, VA Western New York Healthcare System, Buffalo, NY
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- E2902-P
- RX002902 (Other Grant/Funding Number: Veteran Affairs)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frailty
-
University of PennsylvaniaCompleted
-
Instituto Tecnologico y de Estudios Superiores...Not yet recruiting
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
The Hong Kong Polytechnic UniversityCompleted
-
Xijing HospitalUnknownFrailty SyndromeChina
-
Region ZealandUniversity of Southern DenmarkActive, not recruitingFrailty SyndromeDenmark
-
Neurological Associates of West Los AngelesEnrolling by invitation
-
IRCCS Centro San Giovanni di Dio FatebenefratelliCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
Clinical Trials on Short session HIIT
-
Changping LaboratoryBeijing HuiLongGuan HospitalRecruitingTreatment-Resistant DepressionChina
-
Istituti Clinici Scientifici Maugeri SpAUniversita di VeronaActive, not recruitingCopd | Chronic Hypoxemic Respiratory FailureItaly
-
Johns Hopkins Bloomberg School of Public HealthUnited States Agency for International Development (USAID)CompletedPsychological Distress | Engagement, Patient | Psychosocial ProblemUkraine
-
University of Erlangen-Nürnberg Medical SchoolUnknownMetabolic Syndrome | Overweight and ObesityGermany
-
Brigham Young UniversityRecruitingHigh Intensity Interval Training | Aging | Exercise Intolerance | Heat TherapyUnited States
-
University of SevilleRecruitingInsulin Growth Factor I Deficiency | IGF1 Deficiency | Executive Function DisorderSpain
-
USDA Grand Forks Human Nutrition Research CenterCompletedObesity | OverweightUnited States
-
Karolinska InstitutetWithdrawn
-
University of Erlangen-Nürnberg Medical SchoolUnknownHealth Promotion | Primary PreventionGermany
-
Riphah International UniversityRecruiting